{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T05:50:38Z","timestamp":1773985838468,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"31","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,4,27]],"date-time":"2018-04-27T00:00:00Z","timestamp":1524787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.vaccine.2018.04.034","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T02:00:10Z","timestamp":1530151210000},"page":"4750-4758","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study"],"prefix":"10.1016","volume":"36","author":[{"given":"Luis","family":"Rivera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tino F.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Hyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Behre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Ho","family":"Cha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae Sun","family":"Jo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Cheuvart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archana","family":"Jastorff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Van der Wielen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.04.034_b0005","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1586\/erv.12.32","article-title":"MenACWY-TT vaccine for active immunization against invasive meningococcal disease","volume":"11","author":"Papaevangelou","year":"2012","journal-title":"Expert Rev Vaccine"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2018.04.034_b0010","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.034_b0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"key":"10.1016\/j.vaccine.2018.04.034_b0020","unstructured":"World Health Organisation (WHO), Centers for Disease Control and Prevention (CDC). Laboratory methods for the diagnosis of meningitis caused by Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. WHO Manual, 2nd Edition. Chapter 2: Epidemiology of meningitis caused by Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae; 2011, p. 3\u20139. Available at: https:\/\/www.cdc.gov\/meningitis\/lab-manual\/full-manual.pdf. [Accessed August 2017]."},{"key":"10.1016\/j.vaccine.2018.04.034_b0025","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.1016\/j.vaccine.2015.10.055","article-title":"The current situation of meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendations","volume":"33","author":"Safadi","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.034_b0030","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3201\/eid2210.151935","article-title":"Increase in meningococcal serogroup W disease, Victoria, Australia, 2013\u20132015","volume":"22","author":"Carville","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2018.04.034_b0035","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","article-title":"The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines","volume":"59","author":"Pelton","year":"2016","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.vaccine.2018.04.034_b0040","doi-asserted-by":"crossref","first-page":"995","DOI":"10.4161\/hv.27739","article-title":"Review of meningococcal vaccines with updates on immunization in adults","volume":"10","author":"Zahlanie","year":"2014","journal-title":"Hum Vaccine Immunother"},{"key":"10.1016\/j.vaccine.2018.04.034_b0045","unstructured":"EMA. Nimenrix. Summary of product characteristics. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002226\/WC500127663.pdf. [Accessed Ocotber 2017]."},{"key":"10.1016\/j.vaccine.2018.04.034_b0050","first-page":"1825","article-title":"Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix): A review of its immunogenicity, safety, co-administration, and antibody persistence","volume":"12","author":"Assaf-Casals","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.04.034_b0055","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/adc.2006.111500","article-title":"Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines","volume":"92","author":"Pace","year":"2007","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2018.04.034_b0060","unstructured":"FDA. Menactra. Highlights of prescribing information, 2016. Available at: https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm131170.pdf. [Accessed October 2017]."},{"key":"10.1016\/j.vaccine.2018.04.034_b0065","unstructured":"EMA. Menveo. Summary of product characteristics. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001095\/WC500090147.pdf. [Accessed Ocotber 2017]."},{"key":"10.1016\/j.vaccine.2018.04.034_b0070","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.4161\/hv.29571","article-title":"Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia","volume":"10","author":"Ilyina","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.04.034_b0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1586\/erv.10.147","article-title":"Menveo\u00ae: a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y","volume":"10","author":"Cooper","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.04.034_b0080","unstructured":"FDA. Menveo. Highlight of prescribing characteristics. Available at: https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm201349.pdf. [Accessed October 2017]."},{"key":"10.1016\/j.vaccine.2018.04.034_b0085","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1586\/14760584.2016.1130628","article-title":"Routinely vaccinating adolescents against meningococcus: targeting transmission & disease","volume":"15","author":"Vetter","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.04.034_b0090","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1542\/peds.2007-2857","article-title":"Adolescent immunizations: missed opportunities for prevention","volume":"122","author":"Lee","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2018.04.034_b0095","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/INF.0b013e31805d7f17","article-title":"Use of combination vaccines is associated with improved coverage rates","volume":"26","author":"Marshall","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.04.034_b0100","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1017\/S0950268806007151","article-title":"Capture-recapture analysis to estimate the incidence of invasive meningococcal disease in Germany, 2003","volume":"135","author":"Schrauder","year":"2007","journal-title":"Epidemiol Infect."},{"key":"10.1016\/j.vaccine.2018.04.034_b0105","doi-asserted-by":"crossref","first-page":"e44102","DOI":"10.1371\/journal.pone.0044102","article-title":"Laboratory-based surveillance of Neisseria meningitidis isolates from disease cases in Latin American and Caribbean countries, SIREVA II 2006\u20132010","volume":"7","author":"Ibarz-Pav\u00f3n","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.04.034_b0110","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3947\/ic.2016.48.1.12","article-title":"A survey of serum bactericidal antibodies against Neisseria meningitidis serogroups A, C, W and Y in adolescents and adults in the Republic of Korea","volume":"48","author":"Kang","year":"2016","journal-title":"Infect Chemother"},{"key":"10.1016\/j.vaccine.2018.04.034_b0115","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1016\/j.vaccine.2016.10.022","article-title":"Meningococcal disease in the Asia-Pacific region: Findings and recommendations from the Global Meningococcal Initiative","volume":"34","author":"Borrow","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.034_b0120","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3346\/jkms.2017.32.7.1111","article-title":"Characterization of oropharyngeal carriage isolates of Neisseria meningitidis in healthy Korean adolescents in 2015","volume":"32","author":"Kim","year":"2017","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.vaccine.2018.04.034_b0125","first-page":"780","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2018.04.034_b0130","unstructured":"Centers for Disease Control and Prevention (CDC). Inadvertent misadministration of meningococcal conjugate vaccine-\u2013United States, June-August 2005. Available at: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16988640. MMWR Morb Mortal Wkly Rep. 2006;55:1016\u20137."},{"key":"10.1016\/j.vaccine.2018.04.034_b0135","doi-asserted-by":"crossref","first-page":"881","DOI":"10.4161\/hv.6.11.12849","article-title":"Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo(R)) or Menactra(R) among healthy adolescents","volume":"6","author":"Gill","year":"2010","journal-title":"Hum Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.034_b0140","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1016\/j.vaccine.2015.07.019","article-title":"Serum bactericidal antibody assays - The role of complement in infection and immunity","volume":"33","author":"McIntosh","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.034_b0145","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1016\/j.vaccine.2016.05.009","article-title":"Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers","volume":"34","author":"Bona","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.034_b0150","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2018.04.034_b0155","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2018.04.034_b0160","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1128\/CVI.00267-16","article-title":"Immune responses in U.S. military personnel who received meningococcal conjugate vaccine (MenACWY) concomitantly with other vaccines were higher than in personnel who received MenACWY alone","volume":"23","author":"Broderick","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2018.04.034_b0165","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1016\/j.vaccine.2011.03.009","article-title":"An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12\u201323-month-old children","volume":"29","author":"Knuf","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.034_b0170","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/tax006","volume":"24","author":"Tashani","year":"2017","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2018.04.034_b0175","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4161\/hv.7.2.14068","article-title":"Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults","volume":"7","author":"Bermal","year":"2011","journal-title":"Hum Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.034_b0180","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2334-13-116","article-title":"Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study","volume":"13","author":"Borja-Tabora","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2018.04.034_b0185","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40266-013-0065-0","article-title":"Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial","volume":"30","author":"Dbaibo","year":"2013","journal-title":"Drugs Aging"},{"key":"10.1016\/j.vaccine.2018.04.034_b0190","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/INF.0b013e31820e6e02","article-title":"Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile","volume":"30","author":"Memish","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.04.034_b0195","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.4161\/hv.22165","article-title":"A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2\u201310 years","volume":"8","author":"Vesikari","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.04.034_b0200","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00431-012-1924-0","article-title":"Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2\u201310-year-old children: results of an open, randomised, controlled study","volume":"172","author":"Knuf","year":"2013","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.vaccine.2018.04.034_b0205","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.vaccine.2008.08.075","article-title":"Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15\u201325 years","volume":"27","author":"Ostergaard","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.034_b0210","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/21645515.2015.1091908","article-title":"Interactions of conjugate vaccines and co-administered vaccines","volume":"12","author":"Findlow","year":"2016","journal-title":"Hum Vaccine Immunother"},{"key":"10.1016\/j.vaccine.2018.04.034_b0215","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1749-6632.1995.tb44436.x","article-title":"Potential alterations in immunogenicity by combining or simultaneously administering vaccine components","volume":"754","author":"Insel","year":"1995","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.vaccine.2018.04.034_b0220","unstructured":"FDA. Boostrix. Highlights of prescribing information. Available at: https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/ucm152842.pdf. [Accessed in November 2017]."},{"key":"10.1016\/j.vaccine.2018.04.034_b0225","unstructured":"Drugs.com. Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Tetanus Toxoid and Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed. Available at: https:\/\/www.drugs.com\/monograph\/diphtheria-and-tetanus-toxoids-and-acellular-pertussis-vaccine-adsorbed-tetanus-toxoid-and-reduced-diphtheria-toxoid-and-acellular-pertussis-vaccine-adsorbed.html. [Accessed in November 2017]."},{"key":"10.1016\/j.vaccine.2018.04.034_b0230","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.vaccine.2014.09.064","article-title":"Immunogenicity and reactogenicity of Infanrix\u2122 when co-administered with meningococcal MenACWY-TT conjugate vaccine in toddlers primed with MenHibrix\u2122 and Pediarix\u2122","volume":"33","author":"Leonardi","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.034_b0235","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1016\/j.vaccine.2011.03.043","article-title":"Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial","volume":"29","author":"Vesikari","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.034_b0240","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0022-3476(96)70152-X","article-title":"Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants","volume":"129","author":"Schmitt","year":"1996","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2018.04.034_b0245","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.1996.03530250041024","article-title":"Efficacy of acellular pertussis vaccine in early childhood after household exposure","volume":"275","author":"Schmitt","year":"1996","journal-title":"JAMA"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18305176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18305176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:27:10Z","timestamp":1759400830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18305176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":49,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0264410X18305176"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.034","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: A phase III, randomized study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}